8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 28, 2013

BIOJECT MEDICAL TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 0-15360

Oregon	93-1099680
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
7180 SW Sandburg St., Ste. 100 Tigard, Oregon	97223
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (503) 692-8001

Former name or former address if changed since last report:

No Change

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement

On August 28, 2013, Bioject Medical Technologies Inc. (“Bioject”) sold to Mark Logomasini (the “Purchaser”) a Senior Secured Bridge Promissory Note in the amount of $120,000 (the “Note”). The Note is secured by all the intellectual property of Bioject and its wholly owned subsidiary Bioject Inc. Mr. Logomasini is Bioject’s President and Chief Executive Officer and a director. The Note bears interest at the rate of 10% per year with all principal and interest due on or before December 31, 2014, provided that the Note will be prepaid if Bioject can do so but still have adequate cash to fund its ongoing operations for the then forseeable future.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

(a) See Item 1.01 Entry into a Material Definitive Agreement.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibits are filed herewith and this list is intended to constitute the exhibit index:

10.1	Senior Secured Bridge Promissory Note dated August 28, 2013 issued by Bioject Medical Technologies Inc. to Mr. Logomasini.
10.2	Intellectual Property Security Agreement dated August 28, 2013 between Bioject Medical Technologies Inc., Bioject Inc. and Mr. Logomasini.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 30, 2013	BIOJECT MEDICAL TECHNOLOGIES INC.
	(Registrant)
	/s/ CHRISTINE M. FARRELL
	Christine M. Farrell
	Vice President of Finance
	(Principal Financial and Accounting Officer)

2

EX-10.1

Exhibit 10.1

SENIOR SECURED BRIDGE PROMISSORY NOTE

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND HAS BEEN ACQUIRED WITHOUT A VIEW TO DISTRIBUTION AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE NOTE UNDER THE ACT AND UNDER ANY APPLICABLE STATE SECURITIES LAWS, OR AN OPINION OF COUNSEL FOR THE HOLDER (CONCURRED IN BY LEGAL COUNSEL FOR THE CORPORATION) THAT SUCH REGISTRATION IS NOT REQUIRED AS TO SUCH SALE OR OFFER

$120,000 Date: August 28, 2013

For value received, Bioject Medical Technologies Inc., an Oregon corporation (the “Company”), promises to pay to Mark Logomasini (the “Holder”) the principal sum of One Hundred Twenty Thousand and 00/100 dollars ($120,000), together with interest thereon as set forth herein (this “Note”).

The following is a statement of the rights of the Holder and the conditions to which this Note is subject, and to which the Holder, by the acceptance of this Note, agrees:

1. Payment Terms and Security. The unpaid principal balance from time to time outstanding under this Note shall bear interest at the rate of 10% per annum. The outstanding principal balance of and accrued but unpaid interest under this Note shall be repaid by the Company on or before December 31, 2014 (December 31, 2014 or as extended, the “Maturity Date”) unless prepaid or extended pursuant to the terms hereof. Except as otherwise provided herein, both principal and interest shall be payable on the Maturity Date in lawful money of the United States of America to the Holder at the address listed on the signature page hereto (or at such other location as shall be designated by the Holder in a written notice to the Company), in same day funds. This Note is secured by a pledge of all the intellectual property of the Company and its subsidiary, Bioject Inc., pursuant to a Security Agreement in the form attached hereto as Exhibit A.

2. Events of Default. If any of the events specified in this Section 2 shall occur (herein individually referred to as an “Event of Default”), the Holder of the Note may, so long as such condition exists, declare the entire principal and unpaid accrued interest hereon immediately due and payable, without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived:

(a) Default in the payment of the principal and unpaid accrued interest of this Note when due and payable if such default is not cured by the Company within ten (10) business days after the Holder has given the Company written notice of such default; or

1

(b) Any breach by the Company of any representation, warranty, or covenant in this Note; provided, that, in the event of any such breach, to the extent such breach is susceptible to cure, such breach shall not have been cured by the Company within ten (10) business days after written notice to the Company of such breach; or

(c) The Company shall (i) apply for or consent to the appointment of a receiver, trustee, liquidator or custodian of itself or of all or a substantial part of its property, (ii) make a general assignment for the benefit of its or any of its creditors, (iii) be dissolved or liquidated in full or in part, (iv) commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or consent to any such relief or to the appointment of or taking possession of its property by any official in an involuntary case or other proceeding commenced against it or (v) take any action for the purpose of effecting any of the foregoing; or

(d) Proceedings for the appointment of a receiver, trustee, liquidator or custodian of the Company or of all or a substantial part of the property thereof, or an involuntary case or other proceedings seeking liquidation, reorganization or other relief with respect to the Company or the debts thereof under any bankruptcy, insolvency or other similar law now or hereafter in effect shall be commenced and an order for relief entered, or such case or proceeding shall not be dismissed, discharged or stayed within 60 days of commencement.

Notwithstanding anything to the contrary contained herein, if any of the events described in Sections 2(c) or (d) occur, this Note shall be automatically accelerated and the entire principal and unpaid accrued interest thereon shall immediately become due and payable without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived.

3. Mandatory Prepayment. Prior to the Maturity Date, this Note will be prepaid if the Company can do so but still have adequate cash to fund its ongoing operations for the then forseeable future.

4. Assignment. The rights and obligations of the Company and the Holder of this Note shall be binding upon and benefit the successors, assigns, heirs, administrators and transferees of the parties.

5. Waiver and Amendment. Any provision of this Note may be amended, waived or modified upon the written consent of the Company and the Holder. No waiver by any party of any default, misrepresentation, or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder or affect in any way any rights arising because of any prior or subsequent such occurrence.

6. Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile (provided that notice is also given under clause (c) below) if

2

sent during normal business hours of the recipient; if not sent during normal business hours of the recipient, then on the next business day, or (c) upon receipt by the party to be notified by nationally recognized overnight courier service. All communications shall be sent to the party at the address as set forth herein or at such other address as such party may designate by ten (10) days advance written notice to the other party hereto.

7. Governing Law; Waiver of Jury Trial. This Note shall be governed by and construed in accordance with the laws of the state of Oregon, exclusive of conflicts of law provisions. In the event of any dispute between the parties to this Note, the parties agree that the dispute shall be settled in the state or federal courts located in the County of Washington in the State of Oregon. The parties hereto waive all right to trial by jury in any action or proceeding to enforce or defend any rights under this Note.

8. Heading; References. All headings used herein are used for convenience only and shall not be used to construe or interpret this Note. Except where otherwise indicated, all references herein to Sections refer to Sections hereof.

IN WITNESS WHEREOF, each of the Company has executed this Senior Secured Bridge Promissory Note as of the date first above written.

BIOJECT MEDICAL TECHNOLOGIES INC.
By	/s/ Christine M. Farrell
Name: Christine M. Farrell
Title:   Vice President of Finance

3

EX-10.2

Exhibit 10.2

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this “IP Agreement”) is made August 28, 2013 by and among Bioject Medical Technologies Inc. (the “Company”) and its wholly owned subsidiary Bioject Inc. (the “Subsidiary”), each an Oregon corporation, and each with offices at, 7180 SW Sandburg Street, Tigard, Oregon 97223 (collectively, the “Grantors”), and Mark Logomasini, the holders of the Company Senior’s Secured Bridge Promissory Note aggregating $120,000 dated August 28, 2013 (the “Note”) and with the address also set forth on the signature page hereto (the “Noteholder”).

RECITALS

The Noteholder has agreed to make a secured bridge loan to the Company, evidenced by the Note. The Note provides that the Note is secured by all the intellectual property of the Grantors. Accordingly, the Grantors will grant to the Noteholder a security interest in all of Grantors’ right title and interest, whether presently existing or hereafter acquired in, to and under all of the Collateral (as defined therein).

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged and intending to be legally bound, as collateral security for the prompt and complete payment when due of the Note, Grantors hereby represent, warrant, covenant and agree as follows:

1. Grant of Security Interest. As collateral security for the prompt and complete payment and performance of all of Grantors’ present or future obligations under the Note, Grantors hereby grants a security interest in all of Grantors’ right, title and interest in, to and under its registered and unregistered Collateral (all of which shall collectively be called the “Collateral”), including, without limitation, the following:

(a) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on EXHIBIT A attached hereto (collectively, the “Patents”);

(b) Any trademark and service mark rights, slogans, trade dress, and trade names, trade styles, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantors connected with and symbolized by such trademarks, including without limitation those set forth on EXHIBIT A attached hereto (collectively, the “Trademarks”);

(c) Any and all trade secret rights, including any rights to unpatented inventions, know-how, operating manuals, license rights and agreements, and confidential information, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(d) All licenses or other rights to use any of the Patents or Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(e) All amendments, extensions, renewals and extensions of any of the Trademarks, Patents; and

(f) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

1

2. Covenants and Warranties. Grantors represents, warrants, covenants and agrees as follows:

(a) Grantors are the sole owners of the Collateral, except for licenses granted by Grantors to their customers in the ordinary course of business.

(b) Performance of this IP Agreement does not conflict with or result in a breach of any material agreement to which Grantors are bound.

(c) During the term of this IP Agreement, Grantors will not transfer or otherwise encumber any interest in the Collateral, except for licenses granted by Grantors in the ordinary course of business or as otherwise permitted in this IP Agreement;

(d) To their knowledge, each of the Patents is valid and enforceable, and no part of the Collateral has been judged invalid or unenforceable, in whole or in part, and no claim has been made in writing that any part of the Collateral violates the rights of any third party;

(e) Grantors shall advise Noteholder of any subsequent ownership right of the Grantors in or to any Trademark or Patent specified in this IP Agreement;

(f) Grantors shall (i) protect, defend and maintain the validity and enforceability of the Trademarks and Patents material to Grantors’ business, (ii) use reasonable commercial efforts to detect infringements of the Trademarks and Patents, and promptly advise Noteholder in writing of material infringements detected and (iii) not allow any Trademarks and Patents, material to Grantors’ business to be abandoned, forfeited or dedicated to the public without the written consent of Noteholder, which shall not be unreasonably withheld, unless Grantors determine that reasonable business practices suggest that abandonment is appropriate.

(g) Grantors shall take such further actions as Noteholder may reasonably request from time to time to perfect or continue the perfection of Noteholder’s interest in the Collateral;

(h) This IP Agreement creates, and in the case of after acquired Collateral this IP Agreement will create, at the time Grantors first has rights in such after acquired Collateral and Noteholder has taken all actions required for perfection, in favor of Noteholder, a valid and perfected first priority security interest and collateral assignment in the Collateral in the United States securing the payment and performance of the obligations evidenced by the Note;

(i) To its knowledge, except for, and upon, the filing of UCC financing statements, or other notice filings or notations in appropriate filing offices, if necessary to perfect the security interests created hereunder, no authorization, approval or other action by, and no notice to or filing with, any U.S. governmental authority or U.S. regulatory body is required either (a) for the grant by Grantors of the security interest granted hereby, or for the execution, delivery or performance of this IP Agreement by Grantors in the U.S. or (b) for the perfection in the United States or the exercise by Noteholder of its rights and remedies thereunder;

(j) All information heretofore, herein or hereafter supplied to Noteholder by or on behalf of Grantors with respect to the Collateral is true and correct in all material respects.

(k) Grantors shall not enter into any agreement that would materially impair or conflict with Grantors’ obligations hereunder without Noteholder’s prior written consent, which consent shall not be unreasonably withheld. Except as permitted under the Note, Grantors shall not permit the inclusion in any material contract to which it becomes a party of any provisions that could or might in any way prevent the creation of a security interest in Grantors’ rights and interest in any property included within the definition of the Collateral acquired under such contracts.

4. Noteholder’s Rights. Noteholder shall have the right, but not the obligation, to take, at Grantors’ sole expense, any actions that Grantors is required under this IP Agreement to take but which Grantors fails to timely take, after fifteen (15) days’ notice to Grantors. Grantors shall reimburse and indemnify Noteholder for all reasonable costs and reasonable expenses incurred in the reasonable exercise of its rights under this section 4.

2

5. Further Assurances; Attorney in Fact.

(a) On a continuing basis, Grantors will, upon reasonable request by Noteholder, subject to any prior licenses, encumbrances and restrictions and prospective licenses, make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and collateral agreements and filings with the United States Patent and Trademarks Office and the Register of Copyrights, and take all such action as may reasonably be requested by Noteholder, to perfect Noteholder’s security interest in all Patents and Trademarks and otherwise to carry out the intent and purposes of this IP Agreement, or for assuring and confirming to Noteholder the grant or perfection of a security interest in all Collateral, provided that Grantors shall not be required to register any Collateral that Grantors determines, consistent with reasonable business practice, need not be registered.

(b) Grantors appoints Noteholder as Grantor’s attorney-in-fact, with full authority in the place and stead of Grantors and in the name of Grantors, Noteholder or otherwise, from time to time in Noteholder’s discretion, upon Grantor’s failure or inability to do so, to take any action and to execute any instrument which Noteholder may deem reasonably necessary or advisable to accomplish the purposes of this IP Agreement, including:

(i) To modify, in its sole discretion, this IP Agreement without first obtaining Grantor’s approval of or signature to such modification by amending Exhibit A, as appropriate, to include reference to any right, title or interest in any Patents or Trademarks acquired by Grantors after the execution hereof or to delete any reference to any right, title or interest in any Patents or Trademarks Works in which Grantors no longer have or claim any right, title or interest; and

(ii) To file, in its sole discretion, one or more financing or continuation statements and amendments thereto, or other notice filings or notations in appropriate filing offices, relative to any of the Collateral, without notice to Grantors, with all appropriate jurisdictions, as Noteholder deems appropriate, in order to perfect or protect Noteholder’s interest in the Collateral.

6. Events of Default. The occurrence of an Event of Default under the Note shall constitute an Event of Default under this IP Agreement.

7. Remedies. Upon the occurrence and during the continuance of an Event of Default, Noteholder shall have the right to exercise all the remedies of a secured party under the Oregon Uniform Commercial Code, including without limitation the right to require Grantors to assemble the Collateral and any tangible property in which Noteholder have a security interest and to make it available to Noteholder at a place designated by Noteholder. Noteholder shall have a nonexclusive, royalty free license to use the Patents and Trademarks to the extent reasonably necessary to permit Noteholder to exercise their rights and remedies upon the occurrence and during the continuance of an Event of Default. Grantors will pay any expenses (including reasonable attorney’s fees) incurred by Noteholder in connection with the exercise of any of Noteholder’s rights hereunder, including without limitation any expense incurred in disposing of the Collateral in accordance with the terms hereof. All of Noteholder’s rights and remedies with respect to the Collateral shall be cumulative.

8. Indemnity. Grantors agrees to defend, indemnify and hold harmless Noteholder and its agents (each an “Indemnified Person”) against: (a) all obligations, demands, claims, and liabilities (collectively, “Claims”) claimed or asserted by any other party in connection with the transactions contemplated by this IP Agreement, and (b) all losses or expenses in any way suffered, incurred, or paid by Noteholder as a result of or in any way arising out of, following or consequential to transactions between Noteholder and Grantors, under this IP Agreement (including without limitation, reasonable attorney’s fees and reasonable expenses), except for Claims and/or losses arising from or out of an Indemnified Person’s gross negligence or willful misconduct.

9. Termination. At such time as Grantors shall completely repay the Note and any other obligations under the Note, secured hereunder, Noteholder shall execute and deliver to Grantors all releases, terminations, and other instruments as may be necessary or proper to release the security interest hereunder.

3

10. Course of Dealing. No course of dealing, nor any failure to exercise, nor any delay in exercising any right, power or privilege hereunder shall operate as a waiver thereof.

11. Amendments. This IP Agreement may be amended only by a written instrument signed by both parties hereto.

12. Counterparts. This IP Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument.

13. Law and Jurisdiction. This IP Agreement shall be governed by and construed in accordance with the laws of the State of Oregon. GRANTORS ACCEPT FOR THEMSELF AND IN CONNECTION WITH THEIR PROPERTIES, UNCONDITIONALLY, THE NON-EXCLUSIVE JURISDICTION OF ANY STATE OR FEDERAL COURT OF COMPETENT JURISDICTION IN THE STATE OR OREGON IN ANY ACTION, SUIT, OR PROCEEDING OF ANY KIND, AGAINST IT WHICH ARISES OUT OF OR BY REASON OF THIS IP AGREEMENT; PROVIDED, HOWEVER, THAT IF FOR ANY REASON NOTEHOLDER CANNOT AVAIL THEMSELVES OF THE COURTS OF THE STATE OF OREGON, GRANTORS ACCEPTS JURISDICTION OF THE COURTS AND VENUE IN ORANGE COUNTY, CALIFORNIA. NOTWITHSTANDING THE FOREGOING, THE NOTEHOLDER SHALL HAVE THE RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST THE GRANTORS OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH THE NOTEHOLDER DEEMS NECESSARY OR APPROPRIATE IN ORDER TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE THE NOTEHOLDER’ RIGHTS AGAINST THE GRANTORS OR THEIR PROPERTY.

GRANTORS AND NOTEHOLDER EACH HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF ANY OF THE LOAN DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW OR STATUTORY CLAIMS. EACH PARTY RECOGNIZES AND AGREES THAT THE FOREGOING WAIVER CONSTITUTES A MATERIAL INDUCEMENT FOR IT TO ENTER INTO THIS AGREEMENT. EACH PARTY REPRESENTS AND WARRANTS THAT IT HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL AND THAT IT KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

14. Confidentiality. In handling any confidential information, Noteholder shall exercise the same degree of care that they exercise for their own proprietary information, but disclosure of information may be made: (i) to Noteholder or affiliates in connection with their present or prospective business relations with Grantors; (ii) to prospective transferees or purchasers of any interest in the Note (provided, however, Noteholder shall use commercially reasonable efforts to obtain such prospective transferee’s or purchaser’s agreement to the terms of this

4

provision); (iii) as required by law, regulation, subpoena, or other order, (iv) as required in connection with Noteholder’s examination or audit; and (v) as Noteholder considers appropriate in exercising remedies under this Agreement. Confidential information does not include information that either: (a) is in the public domain or in Noteholder’ possession when disclosed to Noteholder, or becomes part of the public domain after disclosure to Noteholder through no fault of Noteholder; or (b) is disclosed to Noteholder by a third party, if Noteholder reasonably does not know that the third party is prohibited from disclosing the information.

Agreed, as of the date first set forth above:

Grantors:

Bioject Medical Technologies Inc.

By:	/s/ Christine M. Farrell
Name: Christine M. Farrell
Title: Vice President of finance

Bioject Inc.

By:	/s/ Christine M. Farrell
Name: Christine M. Farrell
Title: Vice President of Finance

Noteholder:

/s/ Mark Logomasini

Mark Logomasini

5

Exhibit A

SCHEDULE A

Bioject Inc.

Trademark Schedule

Description	Registration/ Application Number	Registration/ Application Date
BIOJECT & Design	2095147	9/9/1997
BIOJECT ZETAJET	4220613	10/9/2012
BIOJECTOR	2095148	9/9/1997
IJECT	2810887	2/3/2004
VITAJET	1838619	6/7/1994
Foreign Trademarks:
B-2000	3300833	12/14/2005
BIOJECT	3301088	1/14/2007
BIOJECT	05925 2003	8/9/2009
BIOJECT & Design	200508684	2/23/2006
BIOJECT ZETAJET	9701257	8/21/2012
BIOJECT ZETAJET	9136094	11/8/2010
BIOJECT ZETAJET	5477139	3/9/2012
BIOJECT and Design	526097	3/30/2000
BIOJECT and Design	497123	3/9/1999
BIOJECT and Design	4172641	7/31/1998
BIOJECTOR & Design	378650	1/25/1991
PETJET	4310215	2/1/2006
VET JET	4310207	2/22/2006

6

SCHEDULE B

Bioject Inc.

Patent Schedule

Description	Registration/ Application Number	Registration/ Application Date
US Patents:
Ampule Filling Device	5,649,912	7/22/1997
Ampule for Needleless Injection	5,503,627	4/2/1996
Disposable Needle-free Injection Apparatus and Method	6,607,510	8/19/2003
Disposable Needle-Free Injection Apparatus and Method	6,471,669	10/29/2002
Disposable Needle-Free Injection Apparatus and Method	6,641,554	11/4/2003
Drug Cartridge Assembly and Method of Manufacture	6,883,222	4/26/2005
Drug Vial Mixing and Transfer Device	5,466,220	11/14/1995
Durable Hypodermic Jet Injector Apparatus and Method	6,752,781	6/22/2004
Durable Needle-less Jet Injector Apparatus and Method	6,648,850	11/18/2003
Electrically Powered Jet Injector	5,505,697	4/9/1996
Ergonomic Needle-less Jet Injection Apparatus and Method	6,572,581	6/3/2003
High Workload Needle-Free Injection System	7,156,823	1/2/2007
Injection Apparatus	D399,951	10/20/1998
Intradermal Injection System for Injecting DNA-Based Injectables into Humans	6,319,224	11/20/2001
Intradermal Injection System for Injecting DNA-Based Injectables into Humans	6,752,780	6/22/2004
Jet Injector Apparatus and Method	6,585,685	7/1/2003
Medication Vial/Syringe Liquid-Transfer Apparatus	5,893,397	4/13/1999
Method for Manufacturing an Ampule	5,312,577	5/17/1994

7

Needle-Free Injection Devices and Drug Delivery Systems Therefor	7,744,563	6/29/2010
Needle-Free Injection System	7,717,874	5/18/2010
Needle-Free Injection System	6,676,630	1/13/2004
Needle-Free Injection System	7,238,167	7/3/2007
Needle-Free Injector and Process for Providing Serial Injections	7,942,845	5/17/2011
Needleless Hypodermic Injection Device	5,383,851	1/24/1995
Needleless Hypodermic Injection Device	5,312,335	5/17/1994
Needleless Hypodermic Injection Methods and Device	5,399,163	3/21/1995
Needleless Hypodermic Injection Methods and Device	5,520,639	5/28/1996
Needle-less Injection System	6,506,177	1/14/2003
Needleless Syringe with Prefilled Cartridge	6,132,395	10/17/2000
Needleless Syringe with Prefilled Cartridge	6,383,168	5/7/2002
NGAS Powered Self-Resetting Needle-Less Hypodermic Jet Injection Apparatus and Method	6,096,002	8/1/2000
Simplified Disposable Needle-Free Injection Apparatus and Method	6,645,170	11/11/2003
Single-use Needle-less Hypodermic Jet Injection Apparatus and Method	6,264,629	7/24/2001
Single-Use Needle-Less Hypodermic Jet Injection Apparatus and Method	6,783,509	8/31/2004
Single-use Needle-less Hypodermic Jet Injection Apparatus and Method	6,689,093	2/10/2004
Spring Powered Needle-Free Injection System	7,442,182	10/28/2008
Triggering Mechanism for a Needle-Free Injector	7,547,293	6/16/2009
Foreign Patents:
Drug Cartridge Assembly and Method of Manufacture	4816/BE/2011	3/11/2011
Drug Cartridge Assembly and Method of Manufacture	1551476	8/28/2003
Drug Cartridge Assembly and Method of Manufacture	1551476	8/28/2003

8

Drug Cartridge Assembly and Method of Manufacture	1551476	3/11/2011
Intradermal Injection System for Injecting DNA-Based Injectables into Humans	1,229,950	5/18/2005
Intradermal Injection System for Injecting DNA-Based Injectables into Humans	ZL 00813342.5	11/2/2005
Medication Vial/Syringe Liquid-Transfer Apparatus	3916713	2/16/2007
Medication Vial/Syringe Liquid-Transfer Apparatus	783879	5/21/2003
Medication Vial/Syringe Liquid-Transfer Apparatus	2,192,623	6/27/2000
Needleless hypodermic Injection Methods and Device	3633615	1/7/2005
Needleless hypodermic Injection Methods and Device	0651663	12/01/1999
Needleless hypodermic Injection Methods and Device	676490	7/10/1997
Needleless hypodermic Injection Methods and Device	2,140,772	7/11/2006
Needleless Syringe with Prefilled Cartridge	2353948	5/20/2008
Needleless syringe with prefilled cartridge	HK1055912	11/18/2005
Needleless Syringe with Prefilled Cartridge	2,407,056	11/18/2008
Needleless Syringe with Prefilled Cartridge	4709461	3/25/2011
Needleless Syringe with Prefilled Cartridge	ZL 01807774.9	6/22/2005
Single-use Needle-less Hypodermic Jet Injection Apparatus and Method	229947	8/12/2005
Single-use Needle-less Hypodermic Jet Injection Apparatus and Method	1202762	7/6/2011

9

Bioject Medical Technologies, Inc.

Trademark Schedule

Description	Registration/ Application Number	Registration/ Application Date
USA Trademarks:
BIOJECT®	2440716	4/3/2001

Patent Schedule

Description	Registration/ Application Number	Registration/ Application Date
USA Patents:
Multiple use needle-less hypodermic injection device for individual users	5782802	7/21/1998

10